| Synaptopathies: synaptic dysfunction in neurological disorders–A review from students to students K Lepeta, MV Lourenco, BC Schweitzer, PV Martino Adami, P Banerjee, ... Journal of neurochemistry 138 (6), 785-805, 2016 | 307 | 2016 |
| Deep eutectic solvents (DESs) are viable cosolvents for enzyme-catalyzed epoxide hydrolysis D Lindberg, M de la Fuente Revenga, M Widersten Journal of biotechnology 147 (3-4), 169-171, 2010 | 285 | 2010 |
| Ayahuasca: Pharmacology, neuroscience and therapeutic potential E Domínguez-Clavé, J Soler, M Elices, JC Pascual, E Álvarez, ... Brain research bulletin 126, 89-101, 2016 | 263 | 2016 |
| Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking KPC Kuypers, J Riba, M de la Fuente Revenga, S Barker, EL Theunissen, ... Psychopharmacology 233, 3395-3403, 2016 | 179 | 2016 |
| The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro JA Morales-García, M De la Fuente Revenga, S Alonso-Gil, ... Scientific reports 7 (1), 5309, 2017 | 168 | 2017 |
| Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities F Sampedro, M de la Fuente Revenga, M Valle, N Roberto, ... International Journal of Neuropsychopharmacology 20 (9), 698-711, 2017 | 156 | 2017 |
| Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice M de la Fuente Revenga, B Zhu, CA Guevara, LB Naler, JM Saunders, ... Cell reports 37 (3), 2021 | 105 | 2021 |
| Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects D Ibi, M de la Fuente Revenga, N Kezunovic, C Muguruza, JM Saunders, ... Nature neuroscience 20 (9), 1247-1259, 2017 | 87 | 2017 |
| Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic … M de la Fuente Revenga, N Fernandez-Saez, C Herrera-Arozamena, ... Journal of Medicinal Chemistry 58 (12), 4998-5014, 2015 | 45 | 2015 |
| Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo M de la Fuente Revenga, JM Shin, HZ Vohra, KS Hideshima, M Schneck, ... Scientific reports 9 (1), 14247, 2019 | 39 | 2019 |
| Cell-type-specific brain methylomes profiled via ultralow-input microfluidics S Ma, M de la Fuente Revenga, Z Sun, C Sun, TW Murphy, H Xie, ... Nature biomedical engineering 2 (3), 183-194, 2018 | 38 | 2018 |
| Recent advances in neurogenic small molecules as innovative treatments for neurodegenerative diseases C Herrera-Arozamena, O Martí-Marí, M Estrada, M De la Fuente Revenga, ... Molecules 21 (9), 1165, 2016 | 38 | 2016 |
| Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: New dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease A Samadi, M de la Fuente Revenga, C Pérez, I Iriepa, I Moraleda, ... European journal of medicinal chemistry 67, 64-74, 2013 | 38 | 2013 |
| Temperature and pH Dependence of Enzyme-Catalyzed Hydrolysis of trans-Methylstyrene Oxide. A Unifying Kinetic Model for Observed Hysteresis, Cooperativity … D Lindberg, M de la Fuente Revenga, M Widersten Biochemistry 49 (10), 2297-2304, 2010 | 38 | 2010 |
| Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity M de la Fuente Revenga, D Ibi, T Cuddy, R Toneatti, M Kurita, MK Ijaz, ... Neuropsychopharmacology 44 (2), 443-454, 2019 | 36 | 2019 |
| HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice M de la Fuente Revenga, D Ibi, JM Saunders, T Cuddy, MK Ijaz, ... Neuroscience 388, 102-117, 2018 | 32 | 2018 |
| Differences in 5-HT2A and mGlu2 receptor expression levels and repressive epigenetic modifications at the 5-HT2A promoter region in the Roman low-(RLA-I) and high-(RHA-I … L Fomsgaard, JL Moreno, M de la Fuente Revenga, T Brudek, ... Molecular neurobiology 55, 1998-2012, 2018 | 31 | 2018 |
| Neurogenic Potential Assessment and Pharmacological Characterization of 6-Methoxy-1, 2, 3, 4-tetrahydro-β-carboline (Pinoline) and Melatonin–Pinoline Hybrids M de la Fuente Revenga, C Perez, JA Morales-Garcia, S Alonso-Gil, ... ACS Chemical Neuroscience 6 (5), 800-810, 2015 | 31 | 2015 |
| The melatonin analog IQM316 may induce adult hippocampal neurogenesis and preserve recognition memories in mice J Figueiro-Silva, D Antequera, C Pascual, M de la Fuente Revenga, ... Cell Transplantation 27 (3), 423-437, 2018 | 26 | 2018 |
| Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice M de la Fuente Revenga, AM Jaster, J McGinn, G Silva, S Saha, ... ACS chemical neuroscience 13 (16), 2436-2448, 2022 | 23 | 2022 |
Jordi RibaMaastricht UniversityDirección de correo verificada de maastrichtuniversity.nl
